Cross-Sector entity
Frontdoor is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. market-trends accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. EVERTEC appears in 4 tracked Cross-Sector stories published from February 25, 2026 through February 27, 2026.
4 verified stories tracked
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Frontdoor is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. market-trends accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. EVERTEC appears in 4 tracked Cross-Sector stories published from February 25, 2026 through February 27, 2026. Each carries 7.8 original sources on average.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering EVERTEC. Shared-story counts are live from our verified record — not editorial picks.
Figure reported a massive 131% increase in blockchain-based loan volume and a 426% surge in EBITDA, signaling a major shift toward institutional DeFi. Payoneer and Evertec also highlighted the growing role of stablecoins and digital rails in global B2B and Latin American payment markets.
A diverse group of mid-cap leaders across home services, healthcare, and fintech are preparing to release their quarterly results. Investors are focused on subscriber retention at Frontdoor and the continued clinical adoption of diagnostics at Natera and Lantheus.
As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.
Investors are closely monitoring upcoming earnings from Natera and Lantheus as bellwethers for the precision medicine and radiopharmaceutical sectors. These reports will highlight the scaling of molecular residual disease testing and the competitive dynamics of advanced prostate cancer imaging.
Source: markets.financialcontent.com · markets.financialcontent.com
